Otsuka has given renal denervation to treat hypertension another vote of confidence. It's signed a distribution deal for certain Asian companies with startup ReCor Medical, as well as making an additional investment in the company.
Wall Street heartily embraced Boston Scientific on its first-quarter earnings, driving shares up about 10% in early trading to give the medical device giant a market cap of nearly $30 billion.
Boston Scientific and Edwards Lifesciences have been scuffling over patents for heart valve replacement devices in Europe. Now, the legal battle is expanding to the U.S. as Boston Scientific vies for more market share.
The medical device industry has been working on miniaturizing pacemakers so they can be minimally invasively inserted and cause fewer difficulties for patients. Up next likely are closed-loop systems: pacemakers that record patient data, transmit that data externally and enable adjustment based on that data by physicians or even, eventually, on their own as guided by advanced algorithms.
Boston Scientific is facing more pushback in its legal saga over vaginal mesh implants. Federal prosecutors are convening a grand jury to consider evidence that the company used defective counterfeit raw materials from China for its devices.
Boston Scientific is recalling all models of its Fetch 2 Aspiration Catheter. The recall of the thrombectomy catheter is due to shaft breakage complaints--and has been classified as Class 1 by the FDA, indicating that use of the device could result in serious adverse health consequences or death.
Boston Scientific has suspended European sales of the CE-marked, Watchman FLX to prevent stroke due to a high embolization rate.
As if the hundreds of millions of dollars in paid out in damages to injured patients aren't enough, Boston Scientific'sntroubled vaginal mesh devices have been hit by allegations that they contain a counterfeit material.
A survey by BMO Capital Markets found that most physicians are abiding by CMS' National Coverage Decision when it comes to implantation of Boston Scientific's Watchman implant to prevent stroke by closing the heart's left atrial appendage.
Boston Scientific launched the Axios Stent and Electrocautery Enhanced Delivery System to minimally invasively treat a couple of serious complications from pancreatitis. The company acquired the technology last April when it bought Mountain View, CA-based startup Xlumena for $75 million plus undisclosed sales milestones.